Agenus | AGEN - Прибыль до налогообложения





Прибыль до налогообложения Изменить Дата
AbbVie USD 4.38B 1.92B 2025-09
Agenus USD -10.61M 263.52M 2025-12
Amgen USD 3.92B 2.35B 2025-09
AstraZeneca USD 3.24B 117M 2025-09
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Celldex Therapeutics USD -81.32M 14.27M 2025-12
CSL USD 2.61B 1.21B 2025-12
Eli Lilly USD 7.23B 456M 2025-09
Gilead Sciences USD 3.64B 1.21B 2025-09
GlaxoSmithKline GBP 1.23B 1.23B 2025-12
Glaxosmithkline GBP 2.46B 569M 2025-09
Incyte USD 389.94M 92.37M 2025-12
Intrexon USD -60.48M 27.09M 2024-06
J&J USD 4.97B 2.53B 2025-12
Jiangsu Hengrui CNY 1.36B 1.61B 2025-09
Karyopharm Therapeutics USD -30.89M 1.16M 2024-12
MacroGenics USD -14.93M 31.75M 2025-12
Merck EUR 1.29B 458.1M 2025-09
Merck USD 6.74B 22M 2025-09
Novartis USD 4.64B 445M 2025-12
Novavax USD 17.9M 220.94M 2025-12
Pfizer USD 3.33B 290M 2025-09
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Rigel Pharmaceuticals USD -1.03M 7.22M 2024-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Veracyte USD 40.63M 21.74M 2025-12